DataSheet_1_DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case–Control Study.docx (2.69 MB)
Download file

DataSheet_1_DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case–Control Study.docx

Download (2.69 MB)
dataset
posted on 09.03.2022, 04:47 authored by Matthias Millesi, Alice Senta Ryba, Johannes A. Hainfellner, Thomas Roetzer, Anna Sophie Berghoff, Matthias Preusser, Gerwin Heller, Erwin Tomasich, Felix Sahm, Karl Roessler, Stefan Wolfsberger
Background

Accounting for 15–20% of all meningiomas, WHO grade II meningiomas represent an intermediate group regarding risk of tumor recurrence. However, even within this subgroup varying clinical courses are observed with potential occurrence of multiple recurrences. Recently, DNA methylation profiles showed their value for distinguishing biological behaviors in meningiomas. Therefore, aim of this study was to investigate DNA methylation profiles in WHO grade II meningiomas.

Methods

All patients that underwent resection of WHO grade II meningiomas between 1993 and 2015 were screened for a dismal course clinical course with ≥2 recurrences. These were matched to control cases with benign clinical courses without tumor recurrence. DNA methylation was assessed using the Infinium Methylation EPIC BeadChip microarray. Unsupervised hierarchical clustering was performed for identification of DNA methylation profiles associated with such a dismal clinical course.

Results

Overall, 11 patients with WHO grade II meningiomas with ≥2 recurrences (Group dismal) and matched 11 patients without tumor recurrence (Group benign) were identified. DNA methylation profiles revealed 3 clusters—one comprising only patients of group dismal, a second cluster comprising mainly patients from group benign and a third cluster comprising one group dismal and one group benign patient. Based on differential methylation pattern associations with the Wnt and the related cadherin signaling pathway was observed.

Conclusion

DNA methylation clustering showed remarkable differences between two matched subgroups of WHO grade II meningiomas. Thus, DNA methylation profiles may have the potential to support prognostic considerations regarding meningioma recurrence and radiotherapeutic treatment allocation after surgical resection.

History

References